Amgen is back in court and this time it s suing FDA. Amgen filed a complaint, posted on FDA Law Blog , on May 25, 2017 after FDA denied the company six months of pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA), for its secondary hyperparathyroidism treatment SensiOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.